Compare Ascendis Pharma A/S (ASND) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Standard Lithium Ltd — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Standard Lithium Ltd trades at $2.46 (market cap $602.91M). The key difference: Ascendis Pharma A/S is far larger — about 29.4× Standard Lithium Ltd's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| ASND | SLI | |
|---|---|---|
Market Cap | $17.74B | $602.91M |
Sector | Health | Basic Materials |
52-Week High | $277.18 | $5.65 |
52-Week Low | $163.32 | $2.29 |
Enterprise Value | $18.11B | $462.10M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Standard Lithium (SLI) trades at $2.46, down 3.15% today, showing bearish technical momentum despite unanimous analyst buy ratings. The company reported negative earnings with Q1 2026 beating expectations but Q4 2025 missing. Strong financing activities of $163.58M in 2025 support development of the South West Arkansas lithium project, with major operational milestones achieved at the demonstration plant.
The investment case hinges on successful project execution and lithium market dynamics. Near-term risks include negative cash flow from operations and high capital expenditures, but the $225M DOE grant and strategic partnerships provide funding stability. Analyst consensus remains strongly bullish with 100% buy ratings, viewing current weakness as a buying opportunity for long-term lithium exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
